Novartis is making further workforce reductions at its U.S. headquarters in New Jersey, planning to eliminate 114 positions ...
The wait is over. Fierce Biotech has released its annual ranking of the top 10 pharma R&D budgets of 2025—offering a clear ...
Despite encountering a legal roadblock last month in his effort to rework the U.S. vaccine infrastructure, HHS secretary ...
Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives with the ...
Amneal and BioCorRx have earned the ire of the FDA’s Office of Prescription Drug Promotion (OPDP), with both being hit by ...
AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount ...
Takeda ended its neurogenerative disease partnership with Denali Therapeutics. Merck & Co. and Zhifei have scrapped a minimum ...
In connection with the deal, Assertio has divested the rest of its assets to New Jersey generics and branded drugmaker ...
Charles River Laboratories has backed an American Heart Association (AHA) campaign, joining forces with the nonprofit on ...
Neurocrine Biosciences, forever a possible M&A target in the biopharma industry, is making a major acquisition itself. | ...
Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results